sGC Activator Avenciguat for CKD

JASN encourages investigators to submit their late-breaking clinical trial manuscripts for rapid consideration and peer review and, if accepted, online publication in JASN concurrent with Kidney Week.

Dr. Hiddo J.L. Heerspink discusses the findings from his study, "Effect of Avenciguat on Albuminuria in Patients with CKD: Two Randomized Placebo-Controlled Trials" with JASN Editor-in-Chief Rajnish Mehrotra.

Drs. Maria Clarissa Tio and Tariq Shafi discuss the findings from their study, "Individualized Risk of CKD Progression among US Adults" with JASN Deputy Editor Manjula Kurella Tamura.

The effect of pantoprazole on eGFR slope, antiviral medications for Herpes Zoster, & link between pediatric AKI in Uzbekistan and cough syrups are covered in this episode of ASN Kidney Translation: An ASN Journals' Podcast.

Andrew Hall discusses results of his study, "Spatiotemporal Landscape of Kidney Tubular Responses to Glomerular Proteinuria," with JASN Deputy Editor David H. Ellison.

Assam El-Osta discusses the findings from his study, "Set7 Methyltransferase and Phenotypic Switch in Diabetic Glomerular Endothelial Cells," with JASN Deputy Editor David H. Ellison.

Jonathan W. Cunningham and Ajay K. Singh discuss the results of their study, "Daprodustat and Heart Failure in CKD," with JASN Deputy Editor David H. Ellison.

Susan R. Mendley and Chyng-Wen Fwu discuss the findings of their study, "Age- and Race-Specific Changes in ESKD Incidence over Four Decades," with JASN Editor-in-Chief Rajnish Mehrotra.

In this podcast, outgoing Editor-in-Chief Josie Briggs talks with incoming Editor-in-Chief Raj Mehrotra about his vision for the next chapter of JASN.

Dr. Briggs and Brendon Neuen discuss his paper in the December issue of JASN. This article on the CREDENCE and EMPA-CKD clinical trials shows that SGLT2 inhibitors allow more consistent use of RAS blockade in patients with declining renal function.